CAR-T cells targeting CD19 have become the leading engineered T-cell therapy approach for relapsed/refractory B-cell non-Hodgkin lymphoma.343 CAR-T therapy can achieve a complete remission rate of more than 50% in relapsed and refractory DLBCL. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.